12 Best Performing Healthcare Stocks to Buy Right Now

Page 7 of 10

4. Guardant Health, Inc. (NASDAQ:GH)

Number of Hedge Fund Holders: 46 

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, specializes in blood-based cancer diagnostics, with its flagship Shield test for colorectal cancer (CRC) using AI-driven liquid biopsy technology.

In September 2025, GH unveiled Shield V2, an upgraded version of its CRC test with improved sensitivity (84%) and specificity (90%), enhancing early cancer detection and potential clinical adoption. GH is also expanding commercial access through partnerships with LabFlorida and PathGroup, reaching over 250 hospitals and health systems across 25 states.

Financial performance shows strong momentum, with revenue rising 30.9% year-over-year and full-year 2025 guidance raised to $915-$925 million, positioning GH among the best performing stocks in the diagnostics sector. Looking ahead, Guardant Health, Inc. (NASDAQ:GH) plans to launch its Shield multi-cancer blood test in October 2025, aiming to detect multiple cancers early and significantly expand its diagnostic portfolio, tapping a market with an estimated $50 billion annual potential. Strategic moves include adding former U.S. Health and Human Services Secretary Alex Azar to the board to support commercialization and regulatory efforts.

The firm is also actively defending its intellectual property, recently filing a lawsuit against Sophia Genetics in Paris over liquid biopsy technology, reinforcing its competitive position in precision oncology.

Page 7 of 10